Join Us

We are 218,061 members in 84 forums discussing 160,867 topics.

Help with Abbreviations

Topic: Breaking Research News from sources other than breastcancer.org

Forum: Clinical Trials, Research News, Podcasts, and Study Results —

Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: Nov 21, 2017 12:31AM - edited Nov 21, 2017 12:35AM by Lumpie

Lumpie wrote:

I watch for research news on breast cancer, treatments, etc., and frequently see interesting articles. There is a topic on BCO called "Breaking Research News from Breastcancer.org." One of the moderators suggested that another topic might be appropriate for posting links and synopses of reports on research found elsewhere. So here it is! Please post links to reports on research form reliable sources. Thanks for sharing!

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Page 77 of 80 (2,374 results)

Posts 2281 - 2310 (2,374 total)

Log in to post a reply

Sep 5, 2020 01:00PM NorCalS wrote:

Lumpie,

Thanks again for the information. I will review and ask MO to help me get into a vaccine clinical trial

Dx: 06/2019, left breast, ER/PR-, Her2-. Treatment: 06/2019 - 11/2019 AC/T. Surgery: Lumpectomy with axillary dissection in 12/2019. Radiation: 01/2020-03/2020. Xeloda - 03/2020-09/2020
Log in to post a reply

Sep 8, 2020 12:51PM AlabamaDee wrote:

Thought I would share


https://clinicaltrials.gov/ct2/show/NCT04288089?term=04288089&draw=2&rank=1#contactlocation

H3B-6545 represents a new class of ERα antagonists discovered by H3 Biomedicine scientists called "Selective Estrogen Receptor Covalent Antagonists" (SERCAs). SERCAs inactivate the estrogen receptor by targeting a cysteine that is not present in the majority of other nuclear hormone receptors. SERCAs have a unique biological activity profile compared to Selective Estrogen Receptor Modulators (SERMs) and Selective Estrogen Receptor Degraders (SERDs).https://www.h3biomedicine.com/2017/09/05/h3-biomedicine-announces-first-patient-dosed-with-h3b-6545-in-phase-1-study-in-breast-cancer/


T
his article says stable and partial response-

https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.1059


Dee

Primary neuroendocrine breast cancer currently in a clinical trial for Pfizer’s CDK 2/4/6 Dx 5/23/2013, Right, 1cm, Stage IIB, Grade 2, 1/22 nodes, ER+/PR+, HER2- (FISH) Chemotherapy 7/29/2013 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 4/2019, Stage IV, metastasized to liver, ER+/PR+, HER2- Targeted Therapy 10/8/2020 Chemotherapy Doxil (doxorubicin) Targeted Therapy Afinitor (everolimus) Hormonal Therapy Faslodex (fulvestrant) Hormonal Therapy Arimidex (anastrozole), Aromasin (exemestane), Fareston (toremifene), Femara (letrozole) Hormonal Therapy Faslodex (fulvestrant) Targeted Therapy Verzenio Chemotherapy Xeloda (capecitabine)
Log in to post a reply

Sep 8, 2020 05:51PM AlabamaDee wrote:

found another one

OP-1250 is a small molecule Complete Estrogen Receptor ANtagonist (CERAN). OP-1250 potently competes with the endogenous activating estrogenic ligand 17-beta estradiol for binding in the ligand binding pocket. OP-1250 blocks estrogen-driven transcriptional activity, inhibits estrogen-driven breast cancer cell growth, and induces degradation of the estrogen

https://clinicaltrials.gov/ct2/show/NCT04505826?term=Sarah+Cannon&recrs=ab&cond=Breast+Cancer&draw=2&rank=2


dee


Primary neuroendocrine breast cancer currently in a clinical trial for Pfizer’s CDK 2/4/6 Dx 5/23/2013, Right, 1cm, Stage IIB, Grade 2, 1/22 nodes, ER+/PR+, HER2- (FISH) Chemotherapy 7/29/2013 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 4/2019, Stage IV, metastasized to liver, ER+/PR+, HER2- Targeted Therapy 10/8/2020 Chemotherapy Doxil (doxorubicin) Targeted Therapy Afinitor (everolimus) Hormonal Therapy Faslodex (fulvestrant) Hormonal Therapy Arimidex (anastrozole), Aromasin (exemestane), Fareston (toremifene), Femara (letrozole) Hormonal Therapy Faslodex (fulvestrant) Targeted Therapy Verzenio Chemotherapy Xeloda (capecitabine)
Log in to post a reply

Sep 9, 2020 01:35AM BSandra wrote:

Dear All, Daiichi Sankyo is about to end another ADC's (Patritumab Deruxtecan, U3-1402) Ph2 clinical trial. It is an interesting ADC that targets HER3 and has to be as effective as DS-8201. Let's keep an eye on that one. Actually I found an interesting link where if you scroll down a bit, you can find a database of all developed ADCs and by using filter "Breast Cancer", you can get all of them related to BC. Just go through them, there are many links to clinical trials in everyone of them: https://www.adcreview.com/drugmap/u3-1402-patritum...

Saulius

Since Sep2019:NED. Feb2019:local recurrence in left breast,IBC. May2018-Feb2019:NED. Jun2018:DC/CIK. Aug2017:stage IV de novo at age 33. Dx 8/4/2017, IDC, Left, 6cm+, Stage IV, metastasized to liver, Grade 2, ER-/PR-, HER2+ (IHC) Chemotherapy 8/26/2017 Taxotere (docetaxel) Targeted Therapy 8/27/2017 Herceptin (trastuzumab) Targeted Therapy 8/27/2017 Perjeta (pertuzumab) Chemotherapy 3/11/2019 Taxotere (docetaxel) Surgery 7/22/2019 Mastectomy: Left Radiation Therapy 9/8/2019 Whole-breast: Lymph nodes, Chest wall
Log in to post a reply

Sep 11, 2020 07:46PM debbew wrote:

Targeting Breast Cancer Cells and Leaving Healthy Cells Unscathed

...Now scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill multiplying human breast cancer cells by selectively attacking the core of their cell division machinery. The method, only tested on lab-grown and patient-derived cancer cells, could advance efforts to find drugs that kill breast cancer cells in a subset of patients...

The research team looked for cell division mechanisms specific to cancer cells in a variety of lab-grown cells. During their search, they encountered a line of human breast cancer cells that are very dependent on cell structures called centrioles to divide and survive....

Further observations revealed that the centriole-dependent breast cancer cells had a section of genome that had been abnormally copied many times, an alteration found in about 9% of breast cancers. The researchers observed the genes encoded in the highly copied region and found a gene that was producing high levels of a protein called TRIM37 shown to control centrosomes...

They used a PLK4 inhibitor known to disrupt proteins that make centrioles, which interfered with TRIM37. When they added the drug to the lab-grown cancer cells with normal TRIM37 levels, they found that the cells were able to divide, even though the drug had removed the cell's centrioles. When the drug was added to breast cancer cells with high TRIM37 levels the cells were not able to divide and most cells stopped growing or died.

"The idea would be to identify tumors with high levels of TRIM37 and use a PLK4 inhibitor to selectively kill cancer cells and leave healthy cells relatively unharmed," explained Holland.

https://www.genengnews.com/news/targeting-breast-c...

paper: https://www.nature.com/articles/s41586-020-2690-1....

Log in to post a reply

Sep 14, 2020 04:28PM Olma61 wrote:

Combining nanotechnology and immunotherapy to fight MBC.


https://medicalxpress.com/news/2020-09-breast-cancer-nanotech-immunotherapy.html


“Efstathios "Stathis" Karathanasis, an associate professor of biomedical engineering, is directing the novel technique—sending nanoparticles into the body to wake up "cold" tumors so they can be located and neutralized by immune cells. The team also includes researchers from Cleveland Clinic and Duke University.“

“The NCI recently awarded a five-year, $3 million grant to Karathanasis and his team to continue their research, initially on animal models with an eye toward human trials. Much of the groundwork behind the project is described in a paper published in Cancer Research, the official journal of the American Association for Cancer Research.

10/30/2017 Xgeva for bone mets 5/31/2018 Taxol finished! "If one just keeps on walking, everything will be all right” - Kierkegaard Dx 8/3/2017, IDC, Right, 2cm, Stage IV, metastasized to bone, Grade 2, ER+/PR+, HER2+ (IHC) Targeted Therapy 10/28/2017 Perjeta (pertuzumab) Targeted Therapy 10/28/2017 Herceptin (trastuzumab) Chemotherapy 10/29/2017 Taxol (paclitaxel) Hormonal Therapy 5/14/2018 Arimidex (anastrozole) Radiation Therapy 5/29/2019 External: Bone
Log in to post a reply

Sep 14, 2020 04:32PM BevJen wrote:

Olma,

Really interesting idea. As with a lot of these great ideas, though, it's not ready for prime time (although a lot of us are!)

Dx 11/2003, ILC, Left, Stage IIIC, ER+/PR+, HER2- Dx 6/2006, ILC, Stage IV, metastasized to other, ER+ Dx 5/2019, ILC, Stage IV, metastasized to liver, ER+/PR+, HER2- Surgery 7/4/2019 Targeted Therapy 7/31/2019 Ibrance (palbociclib) Radiation Therapy Surgery Lymph node removal: Left, Sentinel; Mastectomy: Left, Right; Reconstruction (left): Pedicled TRAM flap; Reconstruction (right): Pedicled TRAM flap Chemotherapy TAC Hormonal Therapy Faslodex (fulvestrant) Hormonal Therapy Tamoxifen pills (Nolvadex, Apo-Tamox, Tamofen, Tamone) Surgery Lymph node removal; Mastectomy; Reconstruction (left): Pedicled TRAM flap; Reconstruction (right): Pedicled TRAM flap Hormonal Therapy Femara (letrozole)
Log in to post a reply

Sep 16, 2020 02:24PM BlueGirlRedState wrote:

Olma61 - interesting idea, waking up cold tumors so that immunotherapy can neutralize them. Kind of scary too, given how hard it is to really treat cancer effectively.

Log in to post a reply

Sep 16, 2020 02:27PM BlueGirlRedState wrote:

Exercise and bone loss. Interesting article on exercise/bone loss in premenopause vs menopause. I wonder if post menopause needs to do more or different exercise to achieve same benefit. Also, which drugs were patients using? I still plan on exercising!! Trying to figure out how to get full article. https://www.practiceupdate.com/journalscan/73090/2/1?elsca1=emc_enews_daily-digest&elsca2=email&elsca3=practiceupdate_onc&elsca4=oncology&elsca5=newsletter&rid=NDg2NTE3NjI4ODEyS0&lid=10332481

Log in to post a reply

Sep 18, 2020 01:17PM - edited Sep 18, 2020 01:23PM by Lumpie

Stereotactic Radiosurgery in Combination With Anti-HER2 Therapy for HER2+ Breast Cancer Brain Metastases
September 14, 2020
Interview with Rupesh R. Kotecha MD
8:20 run time.
Transcript is also available.
{Particularly interesting mention of radiosurgery and concurrent HER2-directed therapy.}
https://www.practiceupdate.com/c/102793/67/13/?els...

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Sep 18, 2020 01:20PM - edited Sep 18, 2020 01:22PM by Lumpie

A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates

Published in Metastatic Breast Cancer - September 17, 2020 (also cited as July 09, 2020)

  • In this study of 16,187 patients with de novo metastatic breast cancer selected from the National Cancer Database (2010–2013), the authors sought to identify prognostic groups using anatomic and biologic factors. Of these patients, 65.2% had a single metastatic site and 42.9% had bone-only metastases. The number of metastatic sites (1 vs >1) and ER status were used as stratification points, along with HER2 and PR status, cT stage, tumor grade, and presence of bone-only metastases. Significant differences in 3-year overall survival were observed among the three groups (stage IVB vs IVA and stage IVC vs IVA).
  • These results support the stratification of patients with de novo metastatic breast cancer into three prognostic groups.

https://www.practiceupdate.com/c/104220/67/13/?els...

https://journals.lww.com/annalsofsurgery/Abstract/...

doi: 10.1097/SLA.0000000000004231


"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Sep 21, 2020 03:55AM BSandra wrote:

Aaa, dear Lumpie, it would be interesting to get whole article... Not very clear who falls into stage A, B or C:/ Saulius

Since Sep2019:NED. Feb2019:local recurrence in left breast,IBC. May2018-Feb2019:NED. Jun2018:DC/CIK. Aug2017:stage IV de novo at age 33. Dx 8/4/2017, IDC, Left, 6cm+, Stage IV, metastasized to liver, Grade 2, ER-/PR-, HER2+ (IHC) Chemotherapy 8/26/2017 Taxotere (docetaxel) Targeted Therapy 8/27/2017 Herceptin (trastuzumab) Targeted Therapy 8/27/2017 Perjeta (pertuzumab) Chemotherapy 3/11/2019 Taxotere (docetaxel) Surgery 7/22/2019 Mastectomy: Left Radiation Therapy 9/8/2019 Whole-breast: Lymph nodes, Chest wall
Log in to post a reply

Sep 21, 2020 05:56AM Olma61 wrote:

I agree Saulius, Sounds so interesting I am tempted to buy access.

10/30/2017 Xgeva for bone mets 5/31/2018 Taxol finished! "If one just keeps on walking, everything will be all right” - Kierkegaard Dx 8/3/2017, IDC, Right, 2cm, Stage IV, metastasized to bone, Grade 2, ER+/PR+, HER2+ (IHC) Targeted Therapy 10/28/2017 Perjeta (pertuzumab) Targeted Therapy 10/28/2017 Herceptin (trastuzumab) Chemotherapy 10/29/2017 Taxol (paclitaxel) Hormonal Therapy 5/14/2018 Arimidex (anastrozole) Radiation Therapy 5/29/2019 External: Bone
Log in to post a reply

Sep 21, 2020 11:39AM Cure-ious wrote:

Oh, I would be so broke if I had to do pay for papers!

Sci-Hub is the link to get access to PubMed behind the paywall; there are many copies of this site out there

https://sci-hub.se/

https://www.sciencemag.org/news/2016/04/whos-downl...

You find and copy the doi number of the paper and paste it into the site, it will be retrieved

Having said that, I tried it just now and the system hung on me.. not sure if its the site or the journal, Annals of Surgery is going to be a pretty rare request In general the site works like a charm, this is the first time I had trouble

Dx 10/2003, IDC, Stage IIB, ER+/PR+, HER2- Dx 7/2015, Stage IV, metastasized to bone, ER+/PR-, HER2-
Log in to post a reply

Sep 23, 2020 06:54AM Olma61 wrote:

thanks for this tip, Cure-ious

10/30/2017 Xgeva for bone mets 5/31/2018 Taxol finished! "If one just keeps on walking, everything will be all right” - Kierkegaard Dx 8/3/2017, IDC, Right, 2cm, Stage IV, metastasized to bone, Grade 2, ER+/PR+, HER2+ (IHC) Targeted Therapy 10/28/2017 Perjeta (pertuzumab) Targeted Therapy 10/28/2017 Herceptin (trastuzumab) Chemotherapy 10/29/2017 Taxol (paclitaxel) Hormonal Therapy 5/14/2018 Arimidex (anastrozole) Radiation Therapy 5/29/2019 External: Bone
Log in to post a reply

Sep 23, 2020 07:14AM BSandra wrote:

Aaa, thanks Cureious, site hangs for me too:/ I am using Firefox... will try other browsers later:) Saulius

Since Sep2019:NED. Feb2019:local recurrence in left breast,IBC. May2018-Feb2019:NED. Jun2018:DC/CIK. Aug2017:stage IV de novo at age 33. Dx 8/4/2017, IDC, Left, 6cm+, Stage IV, metastasized to liver, Grade 2, ER-/PR-, HER2+ (IHC) Chemotherapy 8/26/2017 Taxotere (docetaxel) Targeted Therapy 8/27/2017 Herceptin (trastuzumab) Targeted Therapy 8/27/2017 Perjeta (pertuzumab) Chemotherapy 3/11/2019 Taxotere (docetaxel) Surgery 7/22/2019 Mastectomy: Left Radiation Therapy 9/8/2019 Whole-breast: Lymph nodes, Chest wall
Log in to post a reply

Sep 27, 2020 11:17AM debbew wrote:

Verzenio [reduces risk of] Recurrence and Metastasis of Early Breast Cancer

For people with high-risk HR-positive/HER2-negative early breast cancer, the oral medication Verzenio (abemaciclib) reduced the likelihood of recurrence by 25% when combined with adjuvant (post-surgery) hormone therapy, researchers reported at the European Society for Medical Oncology's ESMO Virtual Congress 2020 and in the Journal of Clinical Oncology.

If approved for this indication, Verzenio has the potential to set a new standard of care, according to lead study investigator Stephen Johnston, MD, PhD, a professor of breast cancer medicine at the Royal Marsden NHS Foundation Trust in London. It is "potentially one of the most notable treatment advances in the last two decades for this population of breast cancer patients," he said in a press release...

Between July 2017 and August 2019, Johnston and colleagues recruited 5,637 people with high-risk HR-positive/HR-negative early breast cancer from 38 countries for a Phase III study known as MonarchE...

At the two-year mark, 7.8% of the participants taking Verzenio had experienced a recurrence compared with 11.3% of the participants not taking Verzenio—a 25% reduction in risk.

Verzenio plus hormone therapy also improved distant relapse-free survival, a measure of the time to metastasis to another part of the body. At the two-year mark, 6.4% of the participants taking Verzenio and 9.7% of the participants not taking the drug had experienced metastasis—a 28% risk reduction...

Even though the study has not yet been completed—final results are projected for delivery in June 2027—Giuseppe Curigliano, MD, PhD, the chair of ESMO's guidelines committee, is optimistic. "This is a very important trial, and the findings will change practice," he said in an ESMO press release.

https://www.cancerhealth.com/article/verzenio-prev...


Log in to post a reply

Sep 27, 2020 11:26AM debbew wrote:

Gut Microbiota May Influence pCR in Early-Stage Breast Cancer

A study out of Scotland, to be presented at this year's virtual European Breast Cancer Conference in October, has linked levels of 2 short-chain fatty acids (SCFAs) in female patients with early-stage breast cancer to pathological complete response (pCR) to neoadjuvant chemotherapy (NACT), according to the abstract released today.

The 2 SCFAs are propionate and butyrate, and they were shown to be lower in the gut bacteria of patients achieving pCR compared with those not achieving pCR after surgery.

"In this study we have started to look at whether the function of the gut microbiome could be one factor that influences the effectiveness of chemotherapy," said Kirsty Ross, MBChB, MSc, a specialist registrar in medical oncology at the Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.

https://www.ajmc.com/view/gut-microbiota-may-influ...

Log in to post a reply

Sep 27, 2020 12:23PM Lumpie wrote:

Palbociclib and Trastuzumab in {HR+}, HER2-Positive Advanced Breast Cancer

September 27, 2020 Clinical Cancer Research

  • The phase II PATRICIA study was designed to evaluate the safety and efficacy of palbociclib plus trastuzumab in postmenopausal women with HR+/HER2+ advanced breast cancer. The median progression-free survival was 10.6 months in patients with luminal B tumors, 8.2 months in patients with luminal A tumors, 4.3 months in those with HER2-enriched breast cancers, and 3.7 months in women with normal-like tumors.
  • The combination of palbociclib and trastuzumab is safe and relatively effective in patients with HR+/HER2+ advanced breast cancer who have progressed on prior treatment. Additional studies are enrolling to test the combination of palbociclib, trastuzumab, and endocrine therapy for superiority over treatment of choice.
https://www.practiceupdate.com/C/106807/56?elsca1=...
https://clincancerres.aacrjournals.org/content/ear...
DOI: 10.1158/1078-0432.CCR-20-0844

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Sep 27, 2020 12:26PM Lumpie wrote:

Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients

September 24, 2020 Journal of Clinical Oncology

  • Patients aged >70 years were randomized to receive trastuzumab monotherapy or trastuzumab plus chemotherapy following surgical management of HER2-positive early breast cancer. Although the 3-year disease-free survival noninferiority primary endpoint for trastuzumab monotherapy was not met, the shorter survival was less than half a month at 3 years. In addition, there was significantly less deterioration in health-related quality of life in the trastuzumab monotherapy group compared with the trastuzumab plus chemotherapy group.
  • Trastuzumab plus chemotherapy should remain the standard of care; however, these results warrant reflection for older patients with contraindications or preference to avoid chemotherapy. Trastuzumab monotherapy may be reasonable for appropriately selected patients.
https://www.practiceupdate.com/C/106744/56?elsca1=...
https://ascopubs.org/doi/10.1200/JCO.20.00184
DOI: 10.1200/JCO.20.00184
"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Sep 28, 2020 12:53PM debbew wrote:

Experimental Cancer Treatment Destroys Cancer Cells [in mice] Without Using Any Drugs

One of the latest methods pioneered by scientists to treat cancer uses a Trojan horse sneak attack to prompt cancer cells to self-destruct – all without using any drugs.

Key to the technique is the use of a nanoparticle coated in a specific amino acid called L-phenylalanine, one of several such acids that cancer cells rely on to grow. L-phenylalanine isn't made by the body, but absorbed from meat and dairy products.

In tests on mice, the nanoparticle – called Nano-pPAAM or Nanoscopic phenylalanine Porous Amino Acid Mimic – killed cancer cells specifically and effectively, posing as a friendly amino acid before causing the cells to destroy themselves.

The self-destruction mode is triggered as the nanoparticle puts production of certain chemicals known as reactive oxygen species (ROS) into overdrive. It's enough to bring down the cancer cells while leaving neighbouring, healthy cells intact...

Nano-pPAAM was shown to kill around 80 percent of breast, skin, and gastric cancer cells in mice, about on a par with current chemotherapy drugs (but without all the side effects of course). While dangerous to cancer cells, it's based on a silica nanoparticle classed as safe to humans by US food regulators.

https://www.sciencealert.com/a-new-cancer-treatmen...


Log in to post a reply

Sep 28, 2020 06:01PM morrigan_2575 wrote:

oh, that's interesting

Dx 1/20/2020, DCIS/IDC, Right, 4cm, Stage IIA, Grade 2, ER+/PR+, HER2+ (IHC) Chemotherapy 2/5/2020 Carboplatin (Paraplatin), Taxotere (docetaxel) Targeted Therapy 2/5/2020 Herceptin (trastuzumab) Targeted Therapy 2/5/2020 Perjeta (pertuzumab) Dx 6/19/2020, DCIS/IDC, Right, <1cm, Stage IA, Grade 2, 1/3 nodes, ER+/PR+, HER2+ Surgery 6/19/2020 Mastectomy: Left, Right; Reconstruction (left): Tissue expander placement; Reconstruction (right): Tissue expander placement Targeted Therapy 7/6/2020 Kadcyla (T-DM1, ado-trastuzumab) Radiation Therapy 8/10/2020 Whole-breast: Breast, Lymph nodes, Chest wall
Log in to post a reply

Sep 29, 2020 08:44AM debbew wrote:

Predictive Analytics Detects Breast Cancer Spread with 90% Accuracy

September 28, 2020 - A predictive analytics method was able to detect with 90 percent accuracy which stage 0 breast cancers [DCIS] are likely to spread and recur, according to a study published in the American Journal of Physiology-Cell Physiology...

The team stained these tissue samples so that the proteins of interest would fluoresce under the microscope. Then, using a computer vision application, researchers created a library of microscope images associated with either aggressive or non-aggressive ductal carcinoma in situ (DCIS) based on what had happened to that patient.

Researchers then showed the program roughly 100 micrographs it hadn't seen before, known as holdout images, to see how well it could accurately predict whether that patient's cancer was likely to recur...

The program is now able to correctly identify aggressive and non-aggressive disease 96 percent of the time, the researchers noted.

"That's pretty impressive when you consider that a human looking at these images would get the answer right about 70 percent of the time," Petty said. "And we've continued to work on reducing the level of false negatives."

The tool also reported false positives in four percent of cases, meaning it identified aggressive disease in patients who did not experience recurrence.

https://healthitanalytics.com/news/predictive-anal...


Log in to post a reply

Sep 30, 2020 10:48AM LillyIsHere wrote:

Advances in Lobular Breast Cancer Research

September 17, 2020

https://my.clevelandclinic.org/podcasts/cancer-adv...

Dx 7/31/2019, ILC, Left, <1cm, Stage IIA, 2/5 nodes, ER+/PR-, HER2- Surgery 9/19/2019 Lymph node removal: Sentinel, Underarm/Axillary; Mastectomy: Left, Right; Prophylactic ovary removal; Reconstruction (left): Silicone implant; Reconstruction (right): Silicone implant Hormonal Therapy 12/1/2019 Femara (letrozole)
Log in to post a reply

Sep 30, 2020 12:26PM - edited Sep 30, 2020 12:27PM by Lumpie

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial


The Lancet Oncology Volume 21, Issue 10, October 2020, Pages 1283-1295


HER2-positive metastatic breast cancer is incurable and new treatments are needed. Addition of atezolizumab to trastuzumab emtansine might potentiate anticancer immunity and enhance the HER2-targeted cytotoxic activity of trastuzumab emtansine. We aimed to test this combination in HER2-positive advanced breast cancer that had progressed after previous treatment with trastuzumab and a taxane.

Addition of atezolizumab to trastuzumab emtansine did not show a clinically meaningful improvement in progression-free survival and was associated with more adverse events. Further study of trastuzumab emtansine plus atezolizumab is warranted in a subpopulation of patients with PD-L1-positive, HER2-positive advanced breast cancer.

https://www.sciencedirect.com/science/article/abs/...

https://doi.org/10.1016/S1470-2045(20)30465-4

{Abstract free; fee for full access unless you have access thru an academic/specialized library.}

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Sep 30, 2020 11:57PM 2019whatayear wrote:

Ugh 2027?

Verenzio -Even though the study has not yet been completed—final results are projected for delivery in June 2027—Giuseppe Curigliano, MD, PhD, the chair of ESMO's guidelines committee, is optimistic. "This is a very important trial, and the findings will change practice," he said in an ESMO press release.

IDC 2 cm micromets 1 node 8 more removed. BMX 6/24, A/C then Taxol 7/25, 25 rads 1/6/2020 No reconstruction BRCA2 - BSO 2/19 all clear/ starting AI on 3/1/2020
Log in to post a reply

Oct 1, 2020 12:27AM Lumpie wrote:

2027 is a bummer, but when they are talking about preventing mets, they have to run the study long enough to see how it preforms over time. I am guessing 2027 is 10 years....?

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Oct 1, 2020 01:53AM BSandra wrote:

2027... Noone will need Verzenio in 2027 anymore after TILs, enhanced CAR-Ts, TCRs, bi/tri-specific antibodies, ADCs with bystander effect, etc. will come in. Giuseppe must be a funny guy...

Saulius

Since Sep2019:NED. Feb2019:local recurrence in left breast,IBC. May2018-Feb2019:NED. Jun2018:DC/CIK. Aug2017:stage IV de novo at age 33. Dx 8/4/2017, IDC, Left, 6cm+, Stage IV, metastasized to liver, Grade 2, ER-/PR-, HER2+ (IHC) Chemotherapy 8/26/2017 Taxotere (docetaxel) Targeted Therapy 8/27/2017 Herceptin (trastuzumab) Targeted Therapy 8/27/2017 Perjeta (pertuzumab) Chemotherapy 3/11/2019 Taxotere (docetaxel) Surgery 7/22/2019 Mastectomy: Left Radiation Therapy 9/8/2019 Whole-breast: Lymph nodes, Chest wall
Log in to post a reply

Oct 1, 2020 11:06AM Lumpie wrote:

FYI: Share will be hosting a program on: Cannabis for Medical Disorders

Dr. Martinez, psychiatrist and a neuroscientist at Columbia University will discuss the research on cannabis for medical disorders, including risks of recreational cannabis use in medically ill patients. She will also discuss sources of cannabis plant extract for neuropathy and pain in cancer patients.

Thursday, 1-2pm ET
October 29

https://www.sharecancersupport.org/cannabis-for-me...


"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Surgery Lumpectomy: Right Surgery Lumpectomy: Right Radiation Therapy Whole-breast: Breast
Log in to post a reply

Oct 2, 2020 09:19AM debbew wrote:

New research sheds light on why tumor cells become resistant to chemotherapy

One way therapy resistance occurs is through hypoxia, or low oxygen levels. Hypoxia can occur within a tumor because it grows much more quickly than the surrounding tissue...

They found that mTOR inhibitors did mimic hypoxia and resulted in the production of different versions of three messenger RNAs (mRNAs), information carriers the body uses to produce proteins from our genes. These different versions are especially suited to allow protein production in stressful cancer conditions such as hypoxia and chemotherapy, and the production of proteins from them leads to tumor progression...

According to the researchers, when an experimental drug called ISRIB that interferes with the reprogramming of protein production—like what is happening with the three mRNAs—was administered, tumor progression was halted.

The findings have led to further questions.

One of the next steps involves looking at whether compounds such as ISRIB—a drug that has been shown to mitigate many negative effects of cancer therapy—can be used to potentially help prevent metastasis and therapy resistance.

https://medicalxpress.com/news/2020-09-tumor-cells...

Page 77 of 80 (2,374 results)